William Oh: Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go

William Oh, Chief Medical Officer at the Prostate Cancer Foundation (PCF), shared on LinkedIn:

“MSK-IMPACT has been a key single source of data regarding the growing influence of precision medicine in cancer. From 2017- 2022, an increase was noted from 8.9% to 31.6% in the fraction of tumors harboring a standard care (Level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying non-actionable drivers (44.2% to 22.8%). Better biology and new targeted therapies is driving more benefit for patients, but there is still a long way to go.”

For the article click here.
Source: William Oh/LinkedIn